Research: Universal Influenza Vaccine
The objective of our research is to develop a universal seasonal vaccine that induces broadly neutralizing antibody responses against influenza viruses spanning the entire diversity of seasonal influenza (type A subtypes H1 and H3 and type B). Our vaccine is epitope-focused and structured-based and includes specifically engineered antigens. Our vaccine presents these antigens on virus-like nanoparticles to amplify immune response.
The influenza vaccine is a $4 billion market worldwide, primarily for seasonal vaccines of limited efficacy that have to be reformulated every year. We anticipate that our vaccine will have a much higher efficacy with a single formulation and high-quality and reliable biologics manufacturing.
The same antigen design and engineering is fully applicable to pandemic influenza vaccines. We are planning to design such universal antigens with a priority for type A subtypes H5 and H7. The major advantage of such a vaccine is that it could be produced and stockpiled prior to any pandemic influenza outbreak.